METHOD FOR EVEROLIMUS THERAPY EFFICIENCY PREDICTION FOR PATIENTS WITH METASTATIC RENAL CANCER Russian patent published in 2017 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: phospho-m-TOR is determined, and HIF-1 hypoxia induced factor,α VEGF vascular endothelial growth factor and its VEGFR2 receptor are determined additionally at the pre-operative treatment stage. At HIF-1α, VEGF, VEGFR2 values in the well of 16.2 AU/mg of protein in the well; 100.5 and 82.2 pg/mg of protein, respectively, as well as phospho-m-TOR levle less than 5.5 pg/mg of protein, high efficiency of everolimus therapy is predicted. At HIF-1α, VEGF, VEGFR2 values less than 16.2 AU/mg of protein in the well, 100.5 and 82.2 pg/mg of protein, respectively, and phospho-m-TOR level more than 5.5 pg/mg of protein, low efficiency of everolimus therapy is predicted.

EFFECT: method provides high accuracy of everolimus therapy efficiency prediction, which, in turn, allows to select the appropriate therapy.

3 ex